Amgen (AMGN) Research & Development (2009 - 2026)
Amgen (AMGN) posted quarterly Research & Development of $1.7 billion for Q1 2026, up 15.68% year-over-year from $1.5 billion in Q1 2025, and down 19.75% quarter-over-quarter from $2.1 billion in Q4 2025.
Amgen (AMGN) Research & Development (2009 - 2026) Analysis & Trends
Amgen's Research & Development history runs 18 years deep, the most recent figure standing at $1.7 billion for Q1 2026.
- In Q1 2026, Research & Development rose 15.68% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.5 billion (up 22.89% YoY), while the FY2025 annual figure was $7.3 billion, up 21.93% from the prior year.
- Research & Development for Q1 2026 stood at $1.7 billion, down from $2.1 billion in the prior quarter.
- The five-year high for Research & Development was $2.1 billion in Q4 2025, with the low at $959.0 million in Q1 2022.
- The 5-year median for Research & Development is $1.4 billion (2024), against an average of $1.4 billion.
- The sharpest annual moves came in 2022 and 2024: Research & Development retreated 21.8% in 2022, then jumped 34.38% in 2024.
- Amgen's Research & Development stood at $1.3 billion in 2022, then advanced by 15.86% to $1.5 billion in 2023, then advanced by 12.39% to $1.7 billion in 2024, then grew by 24.25% to $2.1 billion in 2025, then decreased by 19.75% to $1.7 billion in 2026.
- Business Quant data shows AMGN's Research & Development at $1.7 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.87 Bn |
| Mar 31, 2026 | 1.72 Bn |
| Dec 31, 2025 | 2.14 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 1.74 Bn |
| Mar 31, 2025 | 1.49 Bn |
| Dec 31, 2024 | 1.72 Bn |
| Sep 30, 2024 | 1.45 Bn |
| Jun 30, 2024 | 1.45 Bn |
| Mar 31, 2024 | 1.34 Bn |
| Dec 31, 2023 | 1.53 Bn |
| Sep 30, 2023 | 1.08 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Mar 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 1.32 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 1.04 Bn |
| Mar 31, 2022 | 959.00 Mn |
| Dec 31, 2021 | 1.35 Bn |
| Sep 30, 2021 | 1.42 Bn |